Cantor Fitzgerald Assumes Belite Bio at Overweight, Announces Price Target of $154
Benzinga Newsdesk 11 months ago
NewsPrice TargetInitiationAnalyst Ratings
Cantor Fitzgerald analyst Steve Seedhouse assumes Belite Bio (NASDAQ:BLTE) with a Overweight rating and announces Price Target of $154.
Cantor Fitzgerald analyst Steve Seedhouse assumes Belite Bio (NASDAQ:BLTE) with a Overweight rating and announces Price Target of $154.